NTHI

$3.21-$0.25 (-7.23%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$89.7M

26M shares

52-week range

$3.01 – $12.99

2% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-8.90

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$39990	+0.0%	$-0.70	$-0.96–$-0.54	—	2
2027	$39990	+0.0%	$-0.62	$-0.84–$-0.40	—	2
2028	$39990	+0.0%	$-0.67	$-0.67–$-0.67	—	1
2029	$65M	+162330.6%	$0.58	$0.58–$0.58	5.5×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 0 of the last 4 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-14	$-0.12	$-0.58	-397.1%
2026-05-18	$-0.22	$-0.38	-73.5%
2026-03-31	$-0.37	$-0.40	-7.3%
2025-11-14	$-0.37	$-0.45	-21.6%

NeOnc Technologies Holdings, Inc. Common Stock

NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

www.neonc.com

Employees: 5
IPO / List date: Mar 26, 2025
HQ: CALABASAS, CA

Held by traders on TradeandTell

No one on the platform currently holds NTHI.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in NTHI as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded NTHI yet.

$NTHI chatter on StockTwits

NeOnc Technologies@NeOnc_Technologies9h
@Beroname Appreciate the question. The latest Phase 2a data showed NEO100 met its primary endpoint by more than doubling the pre-specified benchmark (48.9% vs. 20%), while also reporting a median overall survival of 26.1 months. With those results now reported, the program's next milestone is the planned FDA Type B Meeting to discuss a potential registrational pathway. $NTHI
View on StockTwits ↗
NeOnc Technologies@NeOnc_Technologies9h
@Michael1965now Appreciate the comment. For patients facing recurrent high-grade glioma, every meaningful clinical milestone matters. Meeting the primary endpoint and reporting a median overall survival of 26.1 months provide an important foundation for the program's next stage of development. $NTHI
View on StockTwits ↗
NeOnc Technologies@NeOnc_Technologies9h
@TA_Kongen Thanks for revisiting your view. No single study tells the whole story, but meeting the primary endpoint and more than doubling the pre-specified benchmark (48.9% vs. 20%) represent meaningful progress for the program. $NTHI
View on StockTwits ↗
NeOnc Technologies@NeOnc_Technologies10h
Clinical evidence doesn't stop on the day results are announced. Alongside a median overall survival of 26.1 months, five patients remain on NEO100, allowing the program to continue building long-term clinical evidence. $NTHI
View on StockTwits ↗
jorge .miguel@focafoca9911h
$NTHI underscores a strong 2Q26 readout as NEO100 hits 48.9% PFS-6 and median OS 26.1 months, boosting its registrational outlook.
View on StockTwits ↗
TMX Newsfile@newsfile_corp11h
https://nfne.ws/309582 $NTHI #InvestmentBanking #QuarterlyResults #NASDAQ #Investing
View on StockTwits ↗
NeOnc Technologies@NeOnc_Technologies20h
The latest PR highlights more than clinical results; it reinforces the scientific rationale behind NEO100's development. One of the biggest challenges in brain cancer isn't identifying promising therapies, but delivering them across the blood-brain barrier to reach the tumor. NEO100 was specifically designed as an intranasal therapy to bypass that barrier, representing a different approach to drug delivery than conventional systemic administration. That strategy reflects NeOnc's focus on addressing one of the fundamental limitations in treating brain tumors. Innovation in brain cancer isn't only about discovering new molecules; it's also about finding better ways to deliver them where they're needed most. $NTHI $SMMT $CGON $MRK
View on StockTwits ↗
TNN Stock Analysis@TNNStockAnalysisNews1d
Top Stock Gainers Today — Aug 12, 2026 $BOXL — A Financial Runway Play Gains 60% $NOK — European Tech Strength Adds 9.7% $LITE — Optical Component Strength Continues, +7% $DFTX — Phase 3 Data Sparks a 20% Premarket Jump $NTHI — A Clinical Beat Drives Gains https://truthsandnews.com/markets/top-stock-gainers-today-aug-12-2026-ofal
View on StockTwits ↗
NeOnc Technologies@NeOnc_Technologies1d
NEO100 met its primary endpoint, more than doubling the pre-specified benchmark for standard of care (48.9% vs. 20%). Results like these provide the clinical evidence development programs are designed to generate. $NTHI
View on StockTwits ↗
Arcides M.@Arcides1d
$NTHI puking on high volume, probably higher than yesterday massive volume
View on StockTwits ↗
Nick@Nickyboy01d
$NTHI tf happened?
View on StockTwits ↗
Arcides M.@Arcides1d
$NTHI pump and dump bio scam
View on StockTwits ↗
Mark Sanders@dpkingz3051d
$NTHI biggest mistake for me today. Trash lol
View on StockTwits ↗
Rich Goodden@RomuloSkagenBullish1d
$NTHI just guessing, but I suppose the short cash runway is dampening enthusiasm. Time for Shomali to show her value. We’ll see what she comes up with.
View on StockTwits ↗
Nickolas@nick_mBullish1d
$NTHI 🚀🚀🚀🚀
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.